Cingulate Inc. financial data

Symbol
CING, CINGW on Nasdaq
Industry
Pharmaceutical Preparations
Location
1901 W. 47 Th Place, Kansas City, KS
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 43.1 % -47.5%
Debt-to-equity -3.1K % -687%
Return On Equity 11.5K %
Return On Assets -382 % -94.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 951K shares -93.9%
Common Stock, Shares, Outstanding 781K shares -93.5%
Entity Public Float 7.8M USD -32.2%
Common Stock, Value, Issued 78 USD -93.5%
Weighted Average Number of Shares Outstanding, Basic 4.95M shares +775%
Weighted Average Number of Shares Outstanding, Diluted 586K shares -39.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 12.6M USD +18.4%
General and Administrative Expense 6.1M USD -23.9%
Operating Income (Loss) -18.7M USD -0.24%
Nonoperating Income (Expense) -395K USD +34%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -19.1M USD +0.82%
Net Income (Loss) Attributable to Parent -19.1M USD +0.82%
Earnings Per Share, Basic -19.5 USD/shares +45.8%
Earnings Per Share, Diluted -18.2 USD/shares +19.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 381K USD +8.89%
Assets, Current 2.52M USD +23.5%
Property, Plant and Equipment, Net 2.37M USD -11.7%
Operating Lease, Right-of-Use Asset 238K USD -52.7%
Assets 5.13M USD -1.92%
Accounts Payable, Current 1.33M USD -17.5%
Accrued Liabilities, Current 383K USD -62.4%
Liabilities, Current 2.04M USD -81.4%
Operating Lease, Liability, Noncurrent 33.1K USD -91.8%
Liabilities 2.04M USD -82%
Accumulated Other Comprehensive Income (Loss), Net of Tax -3.25K USD
Retained Earnings (Accumulated Deficit) -99.1M USD -23.9%
Stockholders' Equity Attributable to Parent 3.08M USD
Liabilities and Equity 5.13M USD -1.92%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.75M USD -145%
Net Cash Provided by (Used in) Financing Activities 9.89M USD
Net Cash Provided by (Used in) Investing Activities -81.5K USD -119%
Common Stock, Shares Authorized 240M shares 0%
Common Stock, Shares, Issued 781K shares -93.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.06M USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 308 USD -44.5%
Deferred Tax Assets, Valuation Allowance 14.3M USD +62.7%
Deferred Tax Assets, Gross 13.2M USD +123%
Operating Lease, Liability 489K USD -41%
Depreciation 654K USD +46.4%
Payments to Acquire Property, Plant, and Equipment 81.5K USD +119%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -5.98M USD -48.6%
Property, Plant and Equipment, Gross 5.34M USD +6.82%
Operating Lease, Liability, Current 317K USD -8.94%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 6.52M USD +92.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 102M USD +38.3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 564K USD +73%
Interest Expense 634K USD -83.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%